Rigshospitalet Glostrup is located in the township of Glostrup 8 km from the center of Copenhagen in Denmark. It is owned and managed by the regional health authority of the Greater Copenhagen region, Region Hovedstaden. The hospital was formerly known as Glostrup Hospital, but after the merger with Rigshospitalet 1/1/2015, it is now known as Rigshospitalet Glostrup. A teaching hospital for students of multiple vocations, Rigshospitalet Glostrup is affiliated with the University of Copenhagen and more than 200 of its employees hold academic posts at the university, including 14 professorial chairs. It is the primary hospital for the 165,000 citizens of the townships of Albertslund, Ishøj, Høje-Taastrup, Glostrup, and Vallensbæk and as a secondary referral center for larger parts of Region Hovedstaden in neurosurgery, clinical neurophysiology, neurology, and occupational medicine. Several high-profiled subspecialized clinical centers with research activities are incorporated in the departments of the Glostrup Hospital, including the Danish Headache Center.Annual visits number 230,000 patients, including 40,000 in-patients, and 18,000 surgical procedures. With 3,200 employees, 512 beds, Eastern Denmark's largest emergency department and the country's largest ophthalmology department, the Glostrup Hospital is currently undergoing expansion and reorganization to make it a regional and national center in selected specialties while continuing to serve the local community as a general hospital.Architecturally, Rigshospitalet Glostrup is renowned as an example of new public institutions built in the first decades after World War II. Built from the ground in 1952-1958 after an international competition won by architects Martta Martikainen-Ypyä, Ragnar Ypyä, and Veikko Malmio, the hospital was officially inaugurated September 2, 1958 by king Frederick IX of Denmark..
Abstract Background In contrast to pulmonary vein isolation—where procedural workflows and peri-procedural management have become increasingly standardized—LAAC procedures still lack such uniformity. This applies in particular, to the optimal post-procedural antithrombotic strategy. Therefore, the Scientific Initiatives Committee (SIC) of the European Heart Rhythm Association (EHRA) conducted a survey to capture current practice patterns regarding these different aspects, with a specific focus on antithrombotic strategies following LAAC. Methods A structured online questionnaire was developed in the Scientific Initiatives Committee (SIC) and distributed through the European Heart Rhythm Association (EHRA) network and social media. A total of 140 physicians from more than 20 countries participated in the survey. The questionnaire addressed operator background, procedural setting, and antithrombotic regimens at discharge and follow-up. Results Most respondents were electrophysiologists (67.4%; 93/138), with nearly half working in university hospitals (44.9%; 62/138). The majority of centers reported an annual procedural volume of 1–20 LAAC procedures (42.8%). The most common indication for LAAC was a history of major bleeding (64.0% indications). The Watchman FLX (67.4%) and Amulet (66.3%) were the most frequently available devices. Transesophageal echocardiography (TEE) was the preferred imaging modality both pre-procedurally (68.4%) and intra-procedurally (91.9%) and intracardiac echocardiography (ICE) was used by 15.2%. Hospital stay was typically brief (most commonly one night; 58.6%), and late cardiac tamponade was rarely observed (19.4% ever observed, >80% never experienced). Follow-up imaging was performed in most centers (85.9%) after a mean of 10.5 weeks after implantation. In patients undergoing LAAC for bleeding or high bleeding risk, the most frequent discharge regimen was dual antiplatelet therapy (DAPT; 47.9%), typically followed by transition to single antiplatelet therapy (SAPT) after TEE follow-up imaging. In contrast, when LAAC was performed for stroke prevention, direct oral anticoagulation (DOAC) was the preferred regimen at discharge (41.1%; 39/95) and was most commonly (51.2%; 49/95) continued without further adjustment. In cases where treatment was modified, a switch to SAPT was the most frequent adjustment (28.9%; 13/45). Furthermore, peri-device leaks ≥5 mm prompted modification of the antithrombotic regimen in 43.3% of respondents, and 55.8% would consider interventional closure, most commonly using a vascular plug. Conclusion This EHRA survey reveals substantial diversity in post-LAAC antithrombotic management, despite of a high level of procedural consistency. While DAPT and SAPT dominate in bleeding-related indications, DOAC-based strategies remain common in stroke-risk patients. The findings highlight the urgent need for harmonized, evidence-based guidance on antithrombotic therapy following LAAC.
Abstract Background and aims We aimed to investigate the association between major cardiovascular risk factors, including obstructive sleep apnea (OSA) severity, and long-term mortality among patients hospitalized with acute stroke. Methods We conducted a pooled analysis of three previously published studies including patients with ischemic or hemorrhagic stroke admitted to the acute stroke unit at Rigshospitalet Glostrup between 2010 and 2016. All patients underwent overnight polysomnography within the first week of hospital admission. Patients were followed until 1 October 2023. Associations between long-term mortality and cardiovascular risk factors, including OSA, were evaluated using multivariable Cox proportional hazards regression models. Results A total of 137 patients were included. Mean follow-up time from stroke onset to death or end of study period was 9.2 years. Higher OSA severity was associated with increased risk of long-term mortality with a hazard ratio (HR) of 1.14 per 10-unit increase in Apnea-Hypopnea Index (AHI) (95% confidence interval [CI] 1.00–1.29). Increasing age was also associated with higher mortality risk (HR 1.05 per year; 95% CI 1.02–1.09). Patients without Diabetes Type 1 or 2 had a significantly lower risk of long-term mortality (HR 0.18; 95% CI 0.04–0.89 for type 1 Diabetes and HR 0.41; 95% CI 0.20–0.82 for type 2 Diabetes). No significant associations were observed for Atrial fibrillation, Hypertension, Hypercholesterolemia, Body Mass Index, or Barthel Index for Activities of Daily Living. Conclusions Among patients admitted with acute stroke, higher AHI, older age, and a diagnosis of Diabetes at admission were independently associated with increased long-term mortality. Conflict of interest Kathrine B Sondergaard: nothing to disclose. Sofie Amalie Simonsen: nothing to disclose. Laura Bødker Posaing: nothing to disclose. Helle K Iversen: nothing to disclose. Poul Jørgen Jennum: nothing to disclose. Anders Sode West: nothing to disclose.
Abstract Background and aims Circadian disruption is common after stroke, but its impact on diurnal activity during rehabilitation of stroke patients is unclear. This study aimed to examine changes in diurnal activity and melatonin rhythms during stroke rehabilitation, their interrelationship, and the influence of in-hospital lighting. Methods Between May 1, 2014, and June 1, 2015, 29 patients were randomized to rehabilitation with naturalistic lighting (n=16) or standard indoor lighting (n=13). Diurnal activity was measured by actigraphy on the non-paretic arm for seven consecutive days at admission and discharge. Plasma melatonin was sampled at seven time points over a 24-hour period at admission and discharge. Results From admission to discharge, relative nighttime activity decreased compared with daytime activity (mean change −5.12, 95% CI −10.2 to −0.002; p=0.0499), indicating partial restoration of diurnal activity rhythms. At admission, lower night-to-day activity was associated with higher night-to-day melatonin (β −1.78, 95% CI −3.09 to -0.46; p=0.0099). This association was not observed at discharge due to a decrease in nighttime melatonin during hospitalization (median change −3.5, IQR −9.1 to 1.17; p=0.0111). Exposure to naturalistic lighting was not associated with significant changes in activity or melatonin rhythmicity compared with standard indoor lighting. Conclusions Diurnal activity rhythms showed partial restoration during admission, whereas diurnal melatonin rhythms appeared increasingly disrupted. The relationship between activity and melatonin observed at admission was no longer present at discharge, suggesting a disruption of the circadian system during hospitalization. Naturalistic lighting was not associated with measurable changes in diurnal activity or melatonin, possibly due to the small sample size. Conflict of interest Frederik Winsløw: nothing to disclose, Poul Jørgen Jennum: nothing to disclose, Helle Klingenberg Iversen: nothing to disclose, Anders Sode West: nothing to disclose.
Introduction RESOLUTION est un essai clinique de phase IV, randomisé, en double aveugle chez des patients souffrant de migraine chronique et de céphalées par abus médicamenteux selon la classification internationale ICHD-3. Objectifs Evaluer l’efficacité et la sécurité d’emploi d’éptinezumab 100mg vs placebo, en complément d’une intervention éducative sur la surconsommation des traitements de crise. Méthodes RESOLUTION porte sur une période de traitement de 12 semaines en double aveugle évaluant éptinezumab 100mg vs placebo. Le critère d’évaluation principal était la variation du nombre de Jours de Migraine par Mois (JMM) entre la baseline et la période semaines 1 à 4. D’autres évaluations comprenaient notamment un score de douleur, le nombre de traitements de crise consommé par mois, le score PGIC, et un score sur le symptôme le plus gênant. Résultats Sur 608 participants randomisés, 596 (98 %) ont terminé la période contrôlée par placebo. Le critère d’évaluation principal a été atteint, avec une diminution moyenne entre la baseline et la période semaines 1 à 4 de −6,9 JMM avec éptinezumab 100mg contre −3,7 avec le placebo (p<0,0001). Tous les autres critères d’évaluation secondaires sont également statistiquement significatifs. La proportion de patients ayant présenté des événements indésirables était similaire entre les deux groupes. Discussion N.A. Conclusion L’étude RESOLUTION a démontré l’efficacité d’éptinezumab 100mg chez des patients avec un double diagnostic de migraine chronique et de céphalées par abus médicamenteux et confirmé la tolérance précédemment observée.
Abstract Early-stage Parkinson’s disease (PD) presents motor impairments that are difficult to detect clinically. Surface EMG (sEMG) offers an objective alternative, yet many studies rely on non-standardized tasks and provide limited task- and symptom-specific interpretability. This study analyzes sEMG recorded during standardized MDS-UPDRS-III upper-limb tasks—pronation–supination and postural tremor—performed by individuals with early-stage PD (Hoehn and Yahr 1–3, n=31) and healthy controls (n=30). Time-, frequency-, and nonlinear features were extracted and evaluated using a two-stage framework combining filter-based ranking and wrapper-based methods to support feature selection across multiple classifiers and interpretability. Pronation–supination showed the strongest single-task discrimination (balanced accuracy 0.79±0.181), driven by rhythm and nonlinear features reflecting impaired rhythmicity, reduced neuromuscular complexity, and unstable muscle deactivation, consistent with bradykinesia and rigidity. The postural tremor task highlighted tremor-specific spectral changes and reduced signal complexity during sustained posture (balanced accuracy 0.75±0.18), capturing low-frequency oscillations typical of PD tremor. Combining both tasks further improved classification without increasing feature dimensionality (balanced accuracy 0.83±0.186), indicating complementary diagnostic information. Filter-guided selection enhanced robustness and consistency across models. Beyond classification, this study highlights the value of interpretable, task-aligned motor quantification, showing that standardized clinical movements combined with targeted sEMG analysis can support explainable assessment of early-stage PD motor symptoms.